Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the June 30, 2010 issue of Managing Intellectual Property titled “Federal Circuit to re-hear biotech cases post-Bilski.” Brinckerhoff discusses the Supreme Court’s decision to grant certiorari, and then vacate and remand biotech patent case Prometheus v Mayo in light of the decision issued in Bilski v. Kappos. She states that the contested patents in Prometheus should survive since the Federal Circuit has already found that they meet the machine-or-transformation test, but notes that the Bilski decision includes some troubling points for biotech and pharmaceutical patents. She adds that assessing whether a particular patent might promote or impede innovation as a way of determining patent eligibility could be a slippery slope.
People
Related News
July 11, 2025
In the News
Foley Attorneys Assess Critical IP Considerations for Emerging Medical Device Companies
Foley & Lardner LLP attorneys Shabbi Khan, Nate Beaver, Austin Kim, and Jeff Simon authored the Med Device Online article, "Critical Considerations For IP & Patents For Emerging Medical Device Companies."
July 11, 2025
In the News
David Morris Featured for Arrival to Foley's Salt Lake City Office
Foley & Lardner LLP partner David Morris is highlighted across legal press for his recent arrival to the firm.
July 10, 2025
In the News
Ann Marie Uetz Comments on Automotive Supply Chain Approach to Evolving Tariff Environment
Foley & Lardner LLP partner Ann Marie Uetz shared perspective from the automotive supply chain amid the evolving trade environment in the Crain's Detroit article, "Ford, Stellantis tighten terms on suppliers as tariff costs add up."